Fairvalue-Calculator Fairvalue-Calculator
EN DE

Syngen Biotech Co (8279) Fair Value & Analysis

Healthcare · TW · Market cap 2.6B TWD

Price94.70 TWD
Fair Value200.43 TWD
Upside+111.6%
Quality95/100
Evidence: High Range 130.16 TWD – 250.54 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Syngen Biotech Co (8279) currently trades at 94.70 TWD, while our model-based Fair Value estimate is 200.43 TWD — implying the stock looks roughly 111.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredients under the Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL brands; and private labelling services. It also provides organic food OEM/ODM, explosion proof extraction, brand agency, and wholesale distribution services. The company serves the sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox industries. The company was founded in 1988 and is based in Tainan Ci…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Syngen Biotech Co (8279) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 200.43 TWD versus a price of 94.70 TWD — about +112% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 8279?
Our 21-model fair value for Syngen Biotech Co is 200.43 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 94.70 TWD.
What is the quality score of 8279?
Syngen Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.